Navigation Links
OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Date:12/3/2008

    First-line trial currently shows median overall survival of 27.5 months
     for OGX-011 in combination with docetaxel and prednisone and a 16.9
         months overall survival for docetaxel and prednisone alone.

       Achievement of survival benefit milestone results in release of
                   all remaining escrowed shares of OGXI.

BOTHELL, WA and VANCOUVER, Dec. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone ("the OGX-011 arm") compared to docetaxel and prednisone alone ("the control arm") for first-line treatment of metastatic castrate resistant prostate cancer. The current 10.6 month median overall survival advantage observed in the OGX-011 arm represents an increase over the median survival observed in the control arm. Docetaxel was approved by the FDA based on a survival advantage of 2.4 months over mitoxantrone.

Based on the median overall survival advantage, the Board of Directors of OncoGenex Pharmaceuticals has approved the release of all of the remaining shares held in escrow pursuant to agreements related to Sonus Pharmaceuticals' merger with OncoGenex Technologies described in its Proxy Statement filed with the SEC on July 3, 2008. The escrow agreements provided for the release of 50% of the original number of shares held in escrow following the demonstration of at least a two-month improvement in survival in the OGX-011 arm as compared to the control arm. All milestone shares have now been released from escrow; as of December 3, 2008 there are 5,513,643 shares outstanding.

The trial was conducted and data were analyzed by the National Cancer Institute of Canada, Clinical Trials Group and was supported by a grant from the NCI-C
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
2. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
3. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
6. NicOx Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen
7. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
8. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
9. New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD
10. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
11. Jellyfish Protein Shows Potential to Help With Memory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SILVER SPRING, Md. , Dec. 24, 2014  United ... that Medtronic, Inc. (NYSE: MDT ) has ... and Drug Administration (FDA) for the use of Medtronic,s ... a newly developed catheter) for use with United Therapeutics, ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market ... (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, ... Forecasts to 2019” provides a detailed overview of ... trends, and strategies impacting the preparative and process ...
(Date:12/24/2014)... 23, 2014 Earlier this year in a ... of the Adult Stem Cell Technology Center, LLC ( ASCTC ... unique property of adult tissue stem cells. His title ... Important for the Future,” embodied the essence of his message ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... Feb. 25 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, ... on researching,developing, manufacturing and marketing biopharmaceutical products, today,announced ... fourth quarter and,full year ended December 31, 2008 ... 2009. , Following the ...
... DIEGO and MONTREAL, Feb. 25 Speid & ... firm today announced that it has entered into ... rates of new drug compounds using Genizon,s proprietary ... in which innovative pharmaceutical and biotechnology companies have ...
... and SEATTLE, Feb. 24 Implicit,Bioscience Ltd today ... from Eli Lilly and Company. Implicit has paid ... Lilly will also,receive a royalty on future IC14 ... brings substantial expertise and passion to the,treatment of ...
Cached Biology Technology:3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009 2Speid & Associates Partners With Genizon BioSciences to Reduce Attrition Rates of New Drug Compounds 2Implicit Licenses Clinical Stage Antibody Program From Lilly 2Implicit Licenses Clinical Stage Antibody Program From Lilly 3
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication ... success of the Wocket™ smart wallet at CES 2015 in ... as one of the "11 Hot Products at CES" in a review ... So Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" ...
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... addition of the "Global Wearable Technologies Market ... Share, Overview, Trends and Forecast 2014-2020" report ... Technologies are smart devices that can be worn ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... RNA component units called ribonucleotides become embedded in genomic ... organism, they can cause problems for cells. It is ... DNA double helix, resulting in genomic instability and altered ... fate of these ribonucleotides. A new study provides ...
... UCLA life scientists and colleagues have produced the ... health of populations exposed to environmental change. ... Foundation, is published Dec. 2 in the journal ... projection model, or IPM, unites various sub-disciplines of population ...
... Most of us would agree that prevention is better than ... Rehabilitation , published by SAGE, indicate that a costly intervention ... Finland had no measurable effect. , The research was a ... participants and their 2440 matched controls for up to nine ...
Cached Biology News:Study identifies mechanisms cells use to remove bits of RNA from DNA strands 2Powerful mathematical model greatly improves predictions for species facing climate change 2Powerful mathematical model greatly improves predictions for species facing climate change 3Costly intervention program has no measurable effect on early retirement 2Costly intervention program has no measurable effect on early retirement 3
... for easy transformation of the budding yeast, ... transformation simply by mixing a plasmid DNA ... cells. No complicated steps, such as centrifugation ... is particularly well suited for high-throughput transformation ...
... This kit is designed for easy ... The protocol allows for successful transformation simply ... kit reagents with cultured yeast cells. No ... washing, are required. The kit is particularly ...
... your lab productivity and allows you to achieve ... Move ahead beyond traditional paper-based weighing processes into ... *Instruments supported: ... XS, XP, PR, SR, PG-S, PG, SG, AT, ...
XPLAC (S-17)...
Biology Products: